The Cardiovascular research unit, in close collaboration with the “Centre Hospitalier de Luxembourg” (CHL) and the “Institut National de Chirurgie Cardiaque et de Cardiologie Interventionelle” (INCCI), aims to identify novel personalized strategies to diagnose and treat cardiovascular disease. The focus is on the development of heart failure following myocardial infarction and on cardiac arrest.
Ongoing research projects address two major areas:
- Biomarkers: Using high-throughput genomics tools, the team seeks to develop RNA-based diagnostic and prognostic biomarkers for cardiovascular diseases. Research projects focus on non-coding RNAs and have demonstrated a predictive value of 4 microRNAs for left ventricular contractility after acute myocardial infarction.
- Therapeutics: By addressing the mechanisms leading to the development of heart failure, the research group aims to facilitate drug discovery.
The group also coordinates the Cardiolinc network., which is an international effort gathering over 49 collaborators worldwide, to advance in the research deciphering the role of long non-coding RNAs in cardiovascular disease.
Strategic research goals
- Address the main cause of mortality and morbidity in developed countries: cardiovascular disease
- Fulfil unmet medical needs: lack of prognostic tools after an acute cardiac event and lack of effective treatments of heart failure
- Develop a network of international collaborators
- Collaborate with private partners to bring research products to clinical application
- Perform translational research to push forward personalized medicine.
Head of research unit
Dr Yvan Devaux (PhD) joined LIH in 2005 and is currently acting as head of the Cardiovascular Research Unit. His main interest is the discovery of novel RNA biomarkers of cardiac disease. He is founder and chair of the Cardiolinc network.